Boehringer Ingelheim
Overview
Boehringer Ingelheim is a global group of companies dedicated to improving the lives of humans and animals . As one of the world's largest pharmaceutical companies, it focuses on developing innovative therapies in areas of high unmet medical need . The company's key areas of interest include respiratory diseases, metabolism, immunology, oncology, and diseases of the central nervous system .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Click Therapeutics | Apr 2026 | Series D | Lead |
| Click Therapeutics | Apr 2024 | Growth Equity | Co-investor |
| Ilara Health | Feb 2024 | pre-Series A | Co-investor |
| Otto Group | Aug 2023 | Series B | Co-investor |
| Otto | Aug 2023 | Series B | Co-investor |
Key People
Sebastian Kreuz
Executive Director Investment Manager (BI Venture Fund)
Ajith A
Speciality Therapeutic Partner
Daphne Openda
People Partner- Southern Africa OPU
Malcolm Eddie
Head Of Global Support - CRO Strategic Partner Management
Nardjess Nawel Laroussi
Specialty Care Therapy Partner
Swati Choudhary
Learning Partner
Edwin Osas
Senior Principal Consultant CIO Advisory
Anupama Roy
Associate Director- Project & Partner Management, Global Pharmacovigilance
Ali M. YOUSIF
Principal Scientist Head Of Peptide Laboratory
Annett Keller
Senior Principal Statistician, CMC Statistics
Aradhana ‘Ara’ Gupta
Sr. Principal Pathologist
Azar Omrani
Principal Scientist-Head Of Laboratory
Benno Ehrl
Principal Scientist - Head Of Laboratory
Di Feng
Senior Principal Scientist, Computational Biology
Eric Simon
Senior Principal Scientist, Computational Biology, Principal Scientist, Computational Biology Bei Boehringer Ingelheim
Frank Buettner
Senior Principal Scientist - Head Of Laboratory
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
